Home
|
About IAC
|
Contact
|
A-Z Index
|
Donate
|
Shop
|
SUBSCRIBE
Immunization Action Coalition
IAC Home
|
Technically Speaking
|
April 2015
Technically Speaking
Monthly Column by Deborah Wexler, MD
Deborah Wexler MD
Technically Speaking is a monthly column written by IAC’s Executive Director Deborah Wexler, MD. The column is featured in The Children's Hospital of Philadelphia Vaccine Education Center’s (VEC's) monthly e-newsletter for healthcare professionals. Technically Speaking columns cover practical topics in immunization delivery such as needle length, vaccine administration, cold chain, and immunization schedules.
Check out a recent issue of Vaccine Update for Healthcare Providers. The VEC e-newsletter keeps providers up to date on vaccine-related issues and includes reviews of recently published journal articles, media recaps, announcements about new resources, and a regularly updated calendar of events.
TECHNICALLY SPEAKING
Important New Vaccine Recommendations from CDC's February 2015 ACIP Meeting
Published April 2015
The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention meets three times a year, most recently in February. Several important vaccine recommendations were voted upon. ACIP-approved recommendations do not become official until they are approved by the CDC director and published in the Morbidity and Mortality Weekly Report (MMWR). The following provides a summary of the decisions voted upon at the meeting.
Influenza vaccine
ACIP voted to approve its annual influenza vaccine recommendations for the 2015–2016 influenza season. The committee reaffirmed the need for annual influenza vaccination for all people age 6 months and older. Based on new data, ACIP removed the previously recommended preference for the use of live attenuated influenza vaccine (LAIV, FluMist®, AstraZeneca) in children age 2 through 8 years, noting that both LAIV and inactivated influenza vaccine (IIV) are equally acceptable to use in this age group. CDC issued a related media statement on February 26.
Meningococcal B vaccine
ACIP voted that a serogroup B meningococcal vaccine (MenB; Bexsero®, GSK; Trumenba®, Pfizer) series should be administered to people 10 years of age and older who are at increased risk of meningococcal disease. These individuals include:
People with persistent complement component deficiencies, including inherited or chronic deficiencies in C3, C5-9, properdin, factor D, factor H, or taking eculizumab
People with anatomic or functional asplenia, including sickle cell disease
Microbiologists routinely exposed to isolates of Neisseria meningitides
People identified to be at increased risk because of a meningococcal B outbreak
No preference was stated for the use of one MenB vaccine over the other.
Both vaccines are licensed by the Food and Drug Administration (FDA) for use in people ages 10 through 25 years, so administering the vaccine to people age 26 years or older is off-label but recommended by ACIP for people in that age group who are at increased risk for meningococcal disease.
ACIP delayed discussion of routine use of MenB in adolescents and college students until its June meeting.
Human papillomavirus vaccine
ACIP voted to add the newly licensed 9-valent human papillomavirus vaccine (9vHPV, Gardasil® 9, Merck) to the vaccines available for use within the HPV recommendations, i.e., vaccination at age 11 or 12 years, with vaccine use recommended through age 26 for females and through age 21 for males, as well as through age 26 for men who are immunocompromised and men who have sex with men. For females, the 2-valent (Cervarix®, GSK), 4-valent (Gardasil®, Merck), or 9-valent (Gardasil 9, Merck) HPV vaccine may be used, while males should receive either 4-valent or 9-valent HPV vaccine. The 9vHPV vaccine is not yet approved by the FDA for males age 16 through 26 years, so use in this age group is off-label but is ACIP-recommended.
The addition of 9vHPV vaccine to the options of vaccines that may be used to prevent HPV infection had no impact on the recommended vaccine intervals or contraindications for use in pregnant women.
Any HPV vaccine, including 9vHPV, may be used to complete a previously begun HPV vaccine series. ACIP did not address the use of 9vHPV vaccine for persons who have previously completed a full HPV vaccine series.
Updated ACIP HPV recommendations were published on March 27, in MMWR and are available online
In PDF format
In HTML format
Yellow fever vaccine
ACIP voted to recommend that a single dose of yellow fever (YF) vaccine (YF-VAX®, Sanofi) provides long-lasting protection and is adequate for most travelers. ACIP also stated that additional doses of YF vaccine may be indicated for certain populations as follows:
Women who were pregnant when they received their initial dose of YF vaccine should receive one additional dose prior to their next travel that puts them at risk for yellow fever virus infection.
Individuals who received a hematopoietic stem cell transplant after receiving a dose of yellow fever vaccine and who are sufficiently immunocompetent to be safely vaccinated should be revaccinated prior to their next travel that puts them at risk for yellow fever virus infection.
Individuals who were HIV-infected when they received their last dose of YF vaccine should receive a dose every 10 years if they continue to be at risk for yellow fever infection.
Finally, a booster dose of YF vaccine may be considered for travelers who received their last dose of YF vaccine at least 10 years previously and who will be in a higher-risk setting based on season, location, activities and duration of their travel. This would include travelers who plan to spend a prolonged period of time in endemic areas or those traveling to highly endemic areas such as rural West Africa during peak transmission season or areas with ongoing outbreaks.
Related links
ACIP recommendations on IAC's website
ACIP recommendations on CDC's website
ACIP Meeting Information on CDC's website
2015 ISSUES >> view all
DECEMBER 2015
Preventive Medicine: Be Sure Your Staff Is Not Making Any of These Frequently Reported Vaccine Administration Errors
NOVEMBER 2015
IAC's Needle Tips Just Released Online!
OCTOBER 2015
IAC's Free Workshops on Using Standing Orders
SEPTEMBER 2015
New Initiative About Giving Second Dose of Meningococcal (MCV4)
AUGUST 2015
Is Your Practice Following Federal Law When Using Vaccine Information Statements?
JULY 2015
Screening Patients for Contraindications and Precautions to Vaccination
JUNE 2015
Suggestions About Finding Old Immunization Records
MAY 2015
Just Released! Fifth Edition of "The Vaccine Handbook: A Practical Guide for Clinicians"
APRIL 2015
Important New Vaccine Recommendations from CDC's February 2015 ACIP Meeting
MARCH 2015
New Issues of Needle Tips and Vaccinate Adults Now Available
FEBRUARY 2015
CDCís 2015 Immunization Schedules for Children and Adults, and IACís Concise Summaries of Recommendations are Free and Ready to Use
JANUARY 2015
Do You Know Which Vaccines are Specifically Recommended for Healthcare Personnel in Your Workplace?
 
This page was reviewed on May 1, 2015
 
- Guide to immunize.org -
A-Z INDEX
ABOUT IAC
ACIP RECOMMENDATIONS
ADDITIONAL RESOURCES
ADULT VACCINATION
ADULT VACCINATION GUIDE
ASK THE EXPERTS
Combination Vaccines
Diphtheria
Hepatitis A
Hepatitis B
Question of the Week
Vaccine Storage and Handling
What's New
>> view all
BILLING & CODING
BIRTH DOSE GUIDEBOOK
CALENDAR
CDC INFORMATION
CDC SCHEDULES
CLINIC RESOURCES
Administering Vaccines
Documenting Vaccination
Scheduling Vaccination
Screening for Contraindications
Storage & Handling
Vaccine Recommendations
>> view all
COALITIONS
CONTINUING EDUCATION
CONTRIBUTE TO IAC
DEAR COLLEAGUE LETTER
HPV VACCINE
DEAR COLLEAGUE LETTER
MCV4 DOSE #2
DISEASES & VACCINES
Diphtheria
Hepatitis A
Hepatitis B
Influenza
Varicella
>> view all
DONATE TO IAC
EMAIL NEWS SERVICES
EDUCATIONAL MATERIALS
FAQs
FAVORITES (WEB SECTIONS)
FDA PRODUCT APPROVALS
GIVE BIRTH TO THE END OF
HEP B
HANDOUTS FOR PATIENTS &
STAFF
Administering Vaccines
Adult Vaccination
Documenting Vaccinations
Managing Vaccine Reactions
Parent Handouts
Patient Schedules
Questions & Answers
Recommendations
Screening Checklists
Standing Orders
Storage & Handling
Supplies Checklist
Talking with Parents
Temperature Logs
Top Handouts
Translations
Vaccine Index
>> view all
HEPATITIS B BIRTH DOSE
HONOR ROLLS
HepB Birth Dose
Influenza Vaccination for HCP
IAC EXPRESS
IMAGES
IMMUNIZATION TECHNIQUES
DVD
LAMINATED SCHEDULES
MANUFACTURERS
NATIONAL ADULT & INFLUENZA IMMUNIZATION SUMMIT
NEEDLE TIPS
NEWS & INFORMATION
OFFICIAL RELEASES
ACIP
CDC
FDA
>> view all
PACKAGE INSERTS
PARTNERS
PHARMACISTS
PHOTOS
POCKET GUIDES
POWERPOINT SLIDE SETS
PRESS ROOM
PROTECT NEWBORNS
FROM HEP B
PUBLICATIONS
IAC Express
Needle Tips
Vaccinate Adults
THE PURPLE BOOK
QUESTION OF THE WEEK
REGISTRIES
RESOURCE DIRECTORY
SHOP IAC
Immunization Techniques DVD
Laminated Schedules
Patient Record Cards
The Vaccine Handbook:
  A Practical Guide for Clinicians
>> view all
SITE MAP
SLIDE SETS
STANDING ORDERS TEMPLATES
STATE INFORMATION
State Websites
State Laws
State Immunization Managers
>> view all
SUBSCRIBE
SUPPORT IAC
TECHNICALLY SPEAKING
TRANSLATE FOR IAC
TRAVEL (INTERNATIONAL)
UNPROTECTED PEOPLE REPORTS
Chickenpox
Diphtheria
Hepatitis A
Hepatitis B
>> view all
VACCINATE ADULTS
VACCINE CONCERNS
Adjuvants & Ingredients
Alternative Medicine
Autism
Importance of Vaccination
>> view all
THE VACCINE HANDBOOK: A PRACTICAL GUIDE FOR CLINICIANS
VACCINE INFORMATION STATEMENTS
Translations
Vaccine Index
>> view all
VACCINE MANUFACTURERS
VACCINE POLICY & LICENSURE
ACIP
FDA
WHO
>> view all
VACCINE SAFETY
VACCINES & DISEASES
VIDEOS (VIDEO OF THE WEEK)
WHAT'S NEW OR UPDATED AT IAC
Handouts
VISs
Web Sections
>> view all
 
Immunization Action Coalition  •  2550 University Avenue West  •  Suite 415 North  •  Saint Paul, Minnesota  •  55114
tel 651-647-9009  •  fax 651-647-9131
 
 
 
This website is supported in part by a cooperative agreement from the National Center for Immunization and Respiratory Diseases (Grant No. 6NH23IP22550) at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. The website content is the sole responsibility of IAC and does not necessarily represent the official views of CDC.